Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Human studies on the effect of rosiglitazone on inflammatory bowel disease (IBD) are still lacking. We investigated whether rosiglitazone might affect IBD risk by using the reimbursement database of Taiwan’s National Health Insurance to enroll a propensity-score-matched cohort of ever users and neve...

Full description

Bibliographic Details
Main Author: Chin-Hsiao Tseng
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Pharmaceuticals
Subjects:
Crohn’s disease
inflammatory bowel disease
pharmacoepidemiology
rosiglitazone
Taiwan
type 2 diabetes mellitus
Online Access:https://www.mdpi.com/1424-8247/16/5/679

Similar Items

Similar Items